Xtandi, Zytiga Better for African-Americans Than Whites With Advanced Prostate Cancer, Research Finds

Xtandi, Zytiga Better for African-Americans Than Whites With Advanced Prostate Cancer, Research Finds
African-Americans with metastatic castration-resistant prostate cancer live longer after treatment with the androgen inhibitors Zytiga (abiraterone acetate) or Xtandi (enzalutamide) than white men, a new study reports. Historically, African-Americans diagnosed with prostate cancer have had worse survival outcomes than whites. The reasons for this are complex and likely involve a number of interconnected factors, from socioeconomic inequalities to genetic differences. Yet, a new study suggests this disparity isn't present when comparing African-American and white men treate
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *